Indivior PLC stock (US45580R1068): valuation metrics in focus after steady Nasdaq trading

Indivior PLC shares on Nasdaq were little changed around mid-June 2026, keeping attention on how investors value the UK-based addiction-treatment specialist after its latest quarterly earnings and ongoing opioid-related settlements.

Indivior PLC shares traded at USD 15.45 on 06/05/2026 on Nasdaq under the ticker INDV, according to Morningstar as of 06/05/2026, providing a fresh data point on how the United Kingdom-based addiction-treatment group is currently valued in the US market.

The stock gives international investors exposure to a specialist in addiction treatments that is headquartered in the United Kingdom while being listed on Nasdaq in the United States, where trading is concentrated in US dollars.

As of: 06/05/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: INDV
• Sector/industry: Specialty pharmaceuticals, addiction treatment
• Headquarters/country: Slough, United Kingdom
• Core markets: United States, Europe
• Key revenue drivers: Opioid-use disorder therapies and related treatments
• Home exchange/listing venue: Nasdaq (INDV)
• Trading currency: USD

Indivior PLC: core business model

Indivior PLC focuses on developing and marketing prescription medicines for substance-use and mental-health disorders, with revenue primarily generated from opioid-use disorder treatments such as buprenorphine-based therapies.

Valuation metrics and multiples for Indivior PLC

Investors are currently assessing Indivior PLC predominantly through its US listing on Nasdaq, where the share price of USD 15.45 on 06/05/2026 according to Morningstar as of 06/05/2026 implies valuation ratios that can be compared with other specialty pharmaceutical companies.

Based on the companys latest reported financial statements and the recent share price, analysts and market participants track metrics such as the price-to-earnings ratio and enterprise-value-to-EBITDA to understand how Indivior PLC is valued relative to its earnings power and cash generation, although these specific multiples can shift quickly with changes in earnings expectations and ongoing legal or regulatory developments.

Conclusion

The latest Nasdaq price point for Indivior PLC around USD 15.45 on 06/05/2026 according to Morningstar as of 06/05/2026 frames how the market currently values the companys addiction-treatment portfolio and ongoing legal obligations.

With valuation metrics in focus and the business centered on opioid-use disorder therapies, investors will continue to watch how earnings trends, litigation developments and competitive dynamics shape sentiment toward Indivior PLC stock over time.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.